| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | Ft28.80 |
| 52 Week High | Ft28.00 |
| 52 Week Low | Ft26.00 |
| Beta | 0.37 |
| 11 Month Change | -3.36% |
| 3 Month Change | 4.35% |
| 1 Year Change | 17.07% |
| 33 Year Change | 2.86% |
| 5 Year Change | 56.52% |
| Change since IPO | -98.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| CHWGR | LU Pharmaceuticals | LU Market | |
|---|---|---|---|
| 7D | -2.0% | 0% | 0% |
| 1Y | 17.1% | 0% | 0% |
Return vs Industry: CHWGR exceeded the Luxembourg Pharmaceuticals industry which returned 11.6% over the past year.
Return vs Market: CHWGR exceeded the Luxembourg Market which returned 5.3% over the past year.
Price Volatility
| CHWGR volatility | |
|---|---|
| CHWGR Average Weekly Movement | 3.0% |
| Pharmaceuticals Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in LU Market | 0% |
| 10% least volatile stocks in LU Market | 0% |
Stable Share Price: CHWGR has not had significant price volatility in the past 3 months compared to the Luxembourg market.
Volatility Over Time: CHWGR's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1901 | 11,603 | Gabor Orban | www.gedeonrichter.com/hu-hu |
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. researches, develops, manufactures, markets, and sells pharmaceutical products worldwide. It operates through two segments, Pharmaceuticals, and Wholesale and Retail.
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Fundamentals Summary
| CHWGR fundamental statistics | |
|---|---|
| Market cap | US$5.28b |
| Earnings (TTM) | US$613.25m |
| Revenue (TTM) | US$2.17b |
8.6x
P/E Ratio2.4x
P/S RatioIs CHWGR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CHWGR income statement (TTM) | |
|---|---|
| Revenue | Ft811.42b |
| Cost of Revenue | Ft260.03b |
| Gross Profit | Ft551.39b |
| Other Expenses | Ft322.26b |
| Earnings | Ft229.13b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 12, 2024
| Earnings per share (EPS) | 1.26k |
| Gross Margin | 67.95% |
| Net Profit Margin | 28.24% |
| Debt/Equity Ratio | 9.4% |
How did CHWGR perform over the long term?
See historical performance and comparison